Mutation in the Common Docking Domain Affects MAP Kinase ERK2 Catalysis and Stability.
ERK2
MAP kinase
MAPK1
cancer mutations and protein structure alterations
mutation
protein stability
single nucleotide variant
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 May 2023
26 May 2023
Historique:
received:
23
04
2023
revised:
22
05
2023
accepted:
25
05
2023
medline:
10
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
The extracellular-signal-regulated kinase 2 (ERK2), a mitogen-activated protein kinase (MAPK) located downstream of the Ras-Raf-MEK-ERK signal transduction cascade, is involved in the regulation of a large variety of cellular processes. The ERK2, activated by phosphorylation, is the principal effector of a central signaling cascade that converts extracellular stimuli into cells. Deregulation of the ERK2 signaling pathway is related to many human diseases, including cancer. This study reports a comprehensive biophysical analysis of structural, function, and stability data of pure, recombinant human non-phosphorylated (NP-) and phosphorylated (P-) ERK2 wild-type and missense variants in the common docking site (CD-site) found in cancer tissues. Because the CD-site is involved in interaction with protein substrates and regulators, a biophysical characterization of missense variants adds information about the impact of point mutations on the ERK2 structure-function relationship. Most of the P-ERK2 variants in the CD-site display a reduced catalytic efficiency, and for the P-ERK2 D321E, D321N, D321V and E322K, changes in thermodynamic stability are observed. The thermal stability of NP-ERK2 and P-ERK2 D321E, D321G, and E322K is decreased with respect to the wild-type. In general, a single residue mutation in the CD-site may lead to structural local changes that reflects in alterations in the global ERK2 stability and catalysis.
Identifiants
pubmed: 37296900
pii: cancers15112938
doi: 10.3390/cancers15112938
pmc: PMC10252016
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : MIUR Progetti di Ricerca di Rilevante Interesse Nazionale (PRIN) 2017
ID : n. 201744NR8S".
Références
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Methods Enzymol. 2020;638:321-340
pubmed: 32416920
Oncogene. 2007 May 14;26(22):3291-310
pubmed: 17496923
J Biol Chem. 1993 Jul 15;268(20):14553-6
pubmed: 8325833
Cancer Discov. 2018 Feb;8(2):184-195
pubmed: 29247021
J Med Chem. 2015 Jun 11;58(11):4790-801
pubmed: 25977981
Methods Mol Biol. 2012;795:109-18
pubmed: 21960218
J Biol Chem. 2001 Jul 20;276(29):27256-65
pubmed: 11371562
Protein Sci. 2013 Dec;22(12):1698-710
pubmed: 24115095
Protein Sci. 2018 Jan;27(1):293-315
pubmed: 29067766
J Med Chem. 2019 Dec 26;62(24):11004-11018
pubmed: 31710489
ACS Chem Biol. 2019 Jun 21;14(6):1183-1194
pubmed: 31058487
Cancer Res. 2014 Dec 1;74(23):7079-89
pubmed: 25320010
J Biol Chem. 2002 Jan 25;277(4):2629-36
pubmed: 11711538
Signal Transduct Target Ther. 2020 Sep 23;5(1):213
pubmed: 32968059
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):355-67
pubmed: 21460454
J Chem Phys. 2019 Apr 21;150(15):155101
pubmed: 31005085
Connect Tissue Res. 2021 Jul;62(4):475-484
pubmed: 32602381
Virus Res. 2014 Aug 8;188:15-26
pubmed: 24704674
J Biol Chem. 2010 Aug 6;285(32):24871-81
pubmed: 20516075
J Mol Biol. 2003 Nov 28;334(3):527-39
pubmed: 14623192
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2506-11
pubmed: 24550275
Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46
pubmed: 17057753
Bioorg Med Chem Lett. 2015 Jan 15;25(2):192-7
pubmed: 25515559
Cells. 2020 Jan 06;9(1):
pubmed: 31935908
Int J Mol Sci. 2019 Sep 06;20(18):
pubmed: 31489884
Nat Cell Biol. 2000 Feb;2(2):110-6
pubmed: 10655591
Sci Rep. 2015 Jun 08;5:11127
pubmed: 26054059
Mol Cancer Ther. 2020 Feb;19(2):325-336
pubmed: 31744895
Curr Opin Struct Biol. 2005 Aug;15(4):441-6
pubmed: 15993577
J Biol Chem. 2008 Jul 11;283(28):19511-20
pubmed: 18482985
Anal Biochem. 2006 May 15;352(2):198-207
pubmed: 16600168
Clin Cancer Res. 2020 Mar 15;26(6):1229-1236
pubmed: 31848189
Biochemistry. 2010 May 4;49(17):3619-30
pubmed: 20361728
Pharmacol Res. 2012 Aug;66(2):105-43
pubmed: 22569528
Methods Mol Biol. 2017;1607:421-453
pubmed: 28573584
Am J Pathol. 2003 Jun;162(6):1807-15
pubmed: 12759238
J Am Chem Soc. 2005 Aug 3;127(30):10494-5
pubmed: 16045329
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Cell Rep. 2016 Oct 18;17(4):1171-1183
pubmed: 27760319
Cell. 2009 Oct 30;139(3):468-84
pubmed: 19879837
Protein Sci. 2006 Mar;15(3):635-9
pubmed: 16452626
Am J Transplant. 2005 Mar;5(3):443-53
pubmed: 15707398
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Acta Crystallogr D Biol Crystallogr. 2013 Jul;69(Pt 7):1204-14
pubmed: 23793146
Int J Mol Sci. 2017 Feb 10;18(2):
pubmed: 28208577
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Structure. 2006 Jun;14(6):1011-9
pubmed: 16765894
Carcinogenesis. 2010 Apr;31(4):577-86
pubmed: 20097731
Protein Sci. 1993 Nov;2(11):1844-52
pubmed: 8268795
Sci Rep. 2018 Mar 14;8(1):4480
pubmed: 29540703
J Biol Chem. 2010 Jun 25;285(26):20080-7
pubmed: 20378548
Cancer Discov. 2013 Jul;3(7):742-50
pubmed: 23614898
FASEB J. 1995 Jun;9(9):726-35
pubmed: 7601337
Biochemistry. 1988 Oct 18;27(21):8063-8
pubmed: 3233195
Proc Natl Acad Sci U S A. 2019 Jul 30;116(31):15514-15523
pubmed: 31296562